Conference recommendations on immunosuppression practice for adult liver transplantation in Egypt
Authors:
- Nahed A MakhloufNMNahed A Makhlouf
- Iman F MontasserIMIman F Montasser
- Rasha RefaieRRRasha Refaie
- Yasmine M MassoudYMYasmine M Massoud
- Ahmed MarwanAMAhmed Marwan
- Ehab Abdel-KhalekEAEhab Abdel-Khalek
- Hadeel Gamal EldeenHEHadeel Gamal Eldeen
- Mohamad EL TabbakhMTMohamad EL Tabbakh
- Mohamed SaidMSMohamed Said
- Wahid DossWDWahid Doss
- Ayman YosryAYAyman Yosry
- Mohamed Sherif MogawerMMMohamed Sherif Mogawer
Open Access
- 11 May 2026
- journal article
- abstracts
- Published by Springer Nature in Egyptian Liver Journal
- Vol. 16 (1) , 30
Abstract
Background: Adult living donor liver transplantation (LDLT) started in Egypt in 2001, with more than 5000 cases transplanted since then. In Egypt using only ABO compatible donor is the practice in all cases, and up till now, the only oncological indication for LDLT is hepatocellular carcinoma (HCC). The optimal management of the transplant recipient relies on understanding and proper utilization of immunosuppression regimens. The clinician should be aware of how to maintain the delicate balance between under-immunosuppression, leading to graft rejection, and over-immunosuppression, leading to the consequences of immunodeficiency such as sepsis and malignancy. The aim of this consensus is to provide clinical guidance to transplant physicians, transplant surgeons, clinical pharmacologists and nurses about immunosuppression in LDLT recipients. Main body: These national recommendations on immunosuppression in adult LDLT were developed by an experience exchange between the 22 centers currently undergoing LDLT in Egypt. A group of experts in liver transplantation from all over Egypt participated in the review of literature for different aspects related to these recommendations and, then they shared in formulation of several statements. In the United Conference on Hepato-gastroenterology and Infectious Diseases (UCHID) (2022), voting on these statements was done. Conclusion: Comprehensive national guidance is provided regarding the general principles of liver transplant immunosuppression, types of immunosuppression (IS), established IS drugs, types of rejection and their management, treatment of special groups, immunosuppression minimization, immune tolerance and complete IS withdrawal and the role of liver biopsy in orchestrating immunosuppression.Keywords
This publication has 84 references indexed in Scilit:
- Antibody induction versus corticosteroid induction for liver transplant recipientsCochrane Database of Systematic Reviews, 2014
- Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipientsHepatology, 2013
- Sirolimus‐based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma†Hepatology, 2010
- Liver biopsy†Hepatology, 2009
- Graft histology characteristics in long-term survivors of pediatric liver transplantationLiver Transplantation, 2008
- Potential immunological advantage of intravenous mycophenolate mofetil with tacrolimus and steroids in primary deceased donor liver transplantation and live donor liver transplantation without antibody inductionLiver Transplantation, 2008
- Metabolic syndrome in liver transplant recipients: Prevalence and association with major vascular eventsLiver Transplantation, 2007
- Liver biopsy interpretation for causes of late liver allograft dysfunctionHepatology, 2006
- Immunosuppression in liver transplantationLiver Transplantation, 2005
- Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: A protocol with early elimination of steroids and reduction of tacrolimus dosageLiver Transplantation, 2004